Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Tucker

Urology Harrisburg, PA Medical Doctor

NPI 1336149442 CMS profile 196690

815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109

Open in the dashboard

General payments

$2,633

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Tucker of Harrisburg, PA is reported in the CMS Open Payments database as having received $2,633 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $541 14
2024 General $25 1
2023 General $203 6
2022 General $151 7
2021 General $622 38
2020 General $371 23
2019 General $719 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Tucker
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Peter Tucker were reported at $541. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Peter Tucker Urology median Middle half National median
2019 $719 $480 $147–$1,201 $163
2020 $371 $246 $87–$645 $114
2021 $622 $358 $111–$1,000 $132
2022 $151 $476 $143–$1,263 $149
2023 $203 $560 $168–$1,461 $160
2024 $25 $563 $170–$1,464 $164
2025 $541 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $619 13 payments
  2. Astellas Pharma US Inc $531 29 payments
  3. Allergan Inc. $264 19 payments
  4. NeoTract Inc. $170 4 payments
  5. AbbVie, Inc. $155 10 payments
  6. Biogen, Inc. $125 1 payment
  7. Coloplast Corp $114 6 payments
  8. Teleflex LLC $102 4 payments
  9. Boston Scientific Corporation $68 1 payment
  10. Omeros Corporation $55 1 payment
  11. Other $431 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,633 113 payments
Products named General payments · program years 2019–2025
  1. ATRICLIP LAA EXCLUSION SYSTEM $413 8 payments
  2. MYRBETRIQ $299 20 payments
  3. UROLIFT $212 6 payments
  4. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $172 4 payments
  5. BOTOX Urology $151 11 payments
  6. XTANDI $142 10 payments
  7. BOTOX Hyperhydrosis $85 6 payments
  8. LUPRON DEPOT $73 5 payments
  9. General Therapies $68 1 payment
  10. Luja Coude $67 3 payments
  11. Other $696 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

965

Median for Urology: 1,053

Drug cost

$142,536

Median for Urology: $101,464

Branded share of claims

42.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 60 $62,067
Myrbetriq Mirabegron Brand 78 $59,675
Finasteride Generic 198 $3,071
Trimethoprim Generic 27 $2,231
Methenamine Hippurate Generic 19 $2,066
Solifenacin Succinate Generic 48 $2,057
Tamsulosin Hcl Generic 115 $1,922
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 64 $1,793
Silodosin Generic 17 $1,151
Testosterone Cypionate Generic 15 $902

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$77,869

Of which drugs: $5,135

Medicare patients

316

Average age 74

Services billed

1,474

91 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Chronic kidney disease 37%
Diabetes 35%
Ischemic heart disease 33%
Depression 23%
Atrial fibrillation 22%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record